| | |
| Clinical data | |
|---|---|
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 13.7 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H32N2O5 |
| Molar mass | 452.551 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Ensaculin (KA-672) is a drug from the coumarin family, which has been researched as a potential treatment for dementia. It acts on a number of receptor systems, being both a weak NMDA antagonist and a 5HT1A agonist. [1] [2] Animal studies have shown promising nootropic effects, [3] [4] although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic hypotension (low blood pressure upon standing). [5]